Multiple Sclerosis (MS) Clinical Trials

34 recruitingLast updated: June 18, 2026

There are 34 actively recruiting multiple sclerosis (ms) clinical trials across 13 countries. Studies span Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 3, Phase 4. Top locations include San Francisco, California, United States, St Louis, Missouri, United States, Chicago, Illinois, United States. Updated daily from ClinicalTrials.gov.


Multiple Sclerosis (MS) Trials at a Glance

34 actively recruiting trials for multiple sclerosis (ms) are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Not Applicable with 11 trials, with the heaviest enrollment activity in San Francisco, St Louis, and Chicago. Lead sponsors running multiple sclerosis (ms) studies include Tongji Hospital, University Hospital, Basel, Switzerland, and University of California, San Francisco.

Browse multiple sclerosis (ms) trials by phase

Treatments under study

About Multiple Sclerosis (MS) Clinical Trials

Looking for clinical trials for Multiple Sclerosis (MS)? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Multiple Sclerosis (MS) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Multiple Sclerosis (MS) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 34 trials

Recruiting
Phase 3

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Multiple Sclerosis (MS) Primary Progressive
Zenas BioPharma (USA), LLC705 enrolled12 locationsNCT07067463
Recruiting

MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis

Multiple Sclerosis (MS)Cerebral Small Vessel Diseases
Oslo University Hospital1,000 enrolled1 locationNCT07444047
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Early Phase 1

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Tongji Hospital36 enrolled1 locationNCT07337785
Recruiting
Phase 1

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Neuromyelitis Optica Spectrum Disorder (NMOSD)+6 more
Polina Stepensky120 enrolled1 locationNCT07085676
Recruiting
Not Applicable

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

Multiple Sclerosis (MS) - Relapsing-remitting
University of Maryland, Baltimore30 enrolled1 locationNCT06864936
Recruiting
Not Applicable

Combined Motor Imagery and Vestibular Rehab for MS

Multiple Sclerosis (MS) - Relapsing-remitting
Medipol University30 enrolled1 locationNCT07230015
Recruiting
Not Applicable

A Palliative Care Model Impact on Knowledge and Attitudes

Multiple Sclerosis (MS)
Hunter College of City University of New York50 enrolled2 locationsNCT06860932
Recruiting
Not Applicable

Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity

Multiple Sclerosis (MS) - Relapsing-remitting
Centre Hospitalier Universitaire de Nīmes84 enrolled2 locationsNCT07292480
Recruiting
Phase 1Phase 2

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis (MS) Primary ProgressiveMultiple Sclerosis (MS) Secondary Progressive+2 more
Tr1X, Inc.39 enrolled2 locationsNCT07477639
Recruiting
Phase 4

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remitting
Northwestern University40 enrolled1 locationNCT07225361
Recruiting
Phase 1Phase 2

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary Progressive+4 more
University of California, San Francisco74 enrolled1 locationNCT05359653
Recruiting
Not Applicable

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

Multiple Sclerosis (MS) - Relapsing-remittingUpper Extremity Dysfunction
University of Florida15 enrolled2 locationsNCT07376772
Recruiting
Not Applicable

Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences

Multiple Sclerosis (MS)
University Hospital, Basel, Switzerland10 enrolled1 locationNCT04819737
Recruiting
Not Applicable

Effect of Music Therapy on Pain in People With Multiple Sclerosis

Multiple Sclerosis (MS)
Istanbul Bilgi University45 enrolled1 locationNCT06800144
Recruiting
Early Phase 1

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

Multiple Sclerosis (MS) - Relapsing-remitting
Georgia State University25 enrolled2 locationsNCT06629428
Recruiting
Not Applicable

Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)

PARKINSON DISEASE (Disorder)Multiple Sclerosis (MS) - Relapsing-remittingPediatric Patients Affected by Neuromuscolar and Degenerative Diseases
IRCCS Centro Neurolesi Bonino Pulejo300 enrolled1 locationNCT07360977
Recruiting
Not Applicable

Home Based Functional Balance Intervention for Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remittingMultiple Sclerosis (MS) Primary Progressive+2 more
University of Illinois at Chicago75 enrolled1 locationNCT07355387
Recruiting

Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50

Multiple Sclerosis (MS)
University Hospital, Strasbourg, France830 enrolled1 locationNCT07313462
Recruiting

Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis

Multiple Sclerosis (MS)
Assistance Publique - Hôpitaux de Paris80 enrolled1 locationNCT05633875